Last 47 quarters of trend data · Healthcare · Life Science Tools
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | — | 7.76 | 197.93 | 78.71 | 502.17 | — | — | 24.96 | — | — | — | — | — | — | — | — | — | — | — | — | 5877.78 |
| — | — | — | +215.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | 12.23 | 8.54 | 15.65 | 11.07 | 10.13 | 11.24 | — | 9.46 | 12.50 | 11.43 | 10.47 | 6.38 | 6.08 | 6.21 | 4.40 | 5.95 | 3.62 | 6.59 | 10.41 | 13.55 |
| — | +20.7% | -24.0% | — | +17.1% | -19.0% | -1.6% | — | +48.2% | +105.8% | +84.2% | +138.0% | +7.2% | +68.0% | -5.9% | -57.7% | -56.1% | -74.9% | -62.9% | -53.4% | -33.2% | |
| P/B Ratio | — | 3.31 | 2.52 | 3.16 | 3.51 | 2.97 | 3.05 | 3.57 | 3.55 | 3.07 | 2.53 | 2.16 | 1.81 | — | — | 2.14 | 2.38 | 1.42 | 2.00 | 3.23 | 3.75 |
| — | +11.8% | -17.3% | -11.5% | -1.1% | -3.3% | +20.8% | +65.7% | +96.0% | — | — | +0.9% | -23.7% | — | — | -33.8% | -36.5% | -64.2% | -65.2% | -49.6% | -23.6% | |
| P/FCF | — | 53.42 | — | — | 110.90 | 45.76 | 173.41 | 534.70 | 78.38 | 45.11 | — | 136.91 | — | — | — | 57.13 | — | — | — | — | — |
| — | +16.7% | — | — | +41.5% | +1.4% | — | +290.5% | — | — | — | +139.6% | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 186.50 | 320.83 | 40.29 | 247.62 | — | 1561.08 | 95.61 | 386.39 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | -79.4% | -57.9% | -35.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 125.66 | 8626.74 | 82.61 | — | — | — | 58.58 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | +41.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 64.2% | 63.3% | 67.5% | 61.4% | 64.6% | 65.9% | -241.6% | 71.3% | 67.0% | 66.4% | 52.1% | 50.9% | 29.9% | 37.2% | 31.6% | 33.7% | 35.4% | 32.5% | 18.4% | 26.4% |
| — | -0.6% | -4.0% | +127.9% | -14.0% | -3.5% | -0.7% | -563.7% | +40.2% | +124.1% | +78.3% | +65.0% | +50.9% | -15.5% | +14.5% | +71.6% | +27.5% | -12.7% | -41.1% | -66.0% | -53.8% | |
| Operating Margin | — | 6.0% | 0.1% | 31.0% | -0.3% | -65.5% | -5.1% | -40.5% | -5.1% | -18.6% | -17.9% | -42.9% | -37.1% | -38.7% | -34.2% | -23.1% | -22.2% | -21.5% | -30.3% | -48.7% | -33.0% |
| — | +109.1% | +101.9% | +176.5% | +93.8% | -252.6% | +71.5% | +5.5% | +86.3% | +52.0% | +47.7% | -85.7% | -66.9% | -79.8% | -13.0% | +52.7% | +32.7% | -47.3% | -419.5% | -51.6% | -198.9% | |
| Net Margin | — | 158.4% | 4.3% | 18.8% | 2.2% | -62.3% | -1.9% | -363.9% | -5.6% | -105.1% | -55.4% | -77.0% | -123.6% | -25.8% | -36.4% | -111.1% | -24.4% | -179.0% | -19.5% | -40.8% | 0.2% |
| — | +354.3% | +330.5% | +105.2% | +139.7% | +40.7% | +96.6% | -372.8% | +95.5% | -307.1% | -52.4% | +30.8% | -405.7% | +85.6% | -86.5% | -172.4% | -10556.2% | -809.2% | -194.0% | -182.2% | +102.3% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | 11.4% | 0.3% | 1.0% | 0.2% | -4.5% | -0.1% | 3.7% | -0.5% | -6.3% | -3.0% | -4.0% | -95.2% | — | -26.5% | -12.7% | -2.4% | -16.3% | -1.5% | -3.1% | 0.0% |
| — | +351.5% | +349.6% | -73.6% | +133.7% | +28.5% | +95.8% | +192.4% | +99.4% | — | +88.5% | +68.6% | -3823.5% | — | -1697.8% | -305.9% | -14545.8% | -783.6% | -172.8% | -189.0% | +102.2% | |
| ROA | — | 10.6% | 0.3% | 0.9% | 0.2% | -4.0% | -0.1% | 3.2% | -0.5% | -5.3% | -2.5% | -3.2% | -6.9% | -2.3% | -3.1% | -10.5% | -2.1% | -14.3% | -1.3% | -2.7% | 0.0% |
| — | +362.6% | +360.6% | -72.2% | +135.4% | +24.1% | +95.5% | +198.2% | +93.5% | -130.1% | +17.9% | +69.0% | -232.0% | +83.8% | -137.4% | -283.2% | -14337.0% | -791.1% | -173.7% | -176.9% | +102.0% | |
| ROIC | — | 0.3% | 0.0% | 1.2% | -0.0% | -3.8% | -0.3% | 0.3% | -0.3% | -0.8% | -0.7% | -1.6% | -12.0% | — | -12.7% | -1.9% | -1.6% | -1.5% | -1.9% | -3.1% | -2.0% |
| — | +108.6% | +101.8% | +273.7% | +94.4% | -374.4% | +57.3% | +120.9% | +97.1% | — | +94.4% | +15.0% | -646.3% | — | -583.3% | +39.3% | +18.1% | -20.1% | -227.8% | +11.0% | -63.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 0.04 | 0.04 | 0.05 | 0.06 | 0.07 | 0.08 | 0.09 | 0.12 | 0.11 | 0.12 | 0.10 | 0.13 | — | — | 0.12 | 0.11 | 0.07 | 0.05 | 0.06 | 0.06 |
| — | -45.4% | -47.8% | -44.4% | -51.6% | -38.7% | -37.8% | -13.7% | -9.4% | — | — | -16.5% | +16.2% | — | — | +114.7% | +80.7% | -1.1% | -15.7% | +2.9% | +1468.9% | |
| Debt / EBITDA | — | 8.48 | 20.46 | 2.48 | 16.59 | — | 162.34 | 9.77 | 51.80 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | -87.4% | -74.6% | -68.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | — | 9.69 | 7.30 | 5.94 | 4.66 | 4.43 | 4.73 | 4.54 | 2.78 | 2.86 | 2.89 | 2.86 | 2.74 | 3.04 | 2.81 | 3.11 | 3.68 | 3.55 | 3.39 | 3.15 | 3.65 |
| — | +118.8% | +54.3% | +30.8% | +67.8% | +54.8% | +63.7% | +58.9% | +1.4% | -5.8% | +3.0% | -7.9% | -25.5% | -14.3% | -17.2% | -1.4% | +0.9% | -13.0% | -52.4% | -57.3% | -76.1% | |
| Quick Ratio | — | 7.14 | 5.50 | 4.63 | 3.64 | 3.45 | 3.74 | 3.66 | 1.78 | 1.81 | 1.77 | 1.83 | 1.72 | 2.05 | 1.93 | 2.32 | 2.76 | 2.54 | 2.53 | 2.44 | 2.82 |
| — | +106.9% | +47.2% | +26.6% | +104.5% | +91.0% | +111.5% | +100.0% | +3.2% | -11.8% | -8.6% | -21.2% | -37.6% | -19.4% | -23.5% | -4.8% | -1.9% | -21.6% | -60.6% | -63.2% | -79.8% | |
| Interest Coverage | — | — | — | 23.12 | -0.18 | — | — | 43.47 | -5.48 | -3.62 | -14.70 | -25.48 | -59.96 | -13.25 | -32.14 | -25.53 | -726.73 | -2383.88 | -42.59 | -152.83 | -56.46 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BLFS stock.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioLife Solutions, Inc.'s business trajectory between earnings reports.